4D Molecular Therapeutics (FDMT) Consolidated Net Income (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Consolidated Net Income of -$68.8 million for Q1 2026, down 43.13% year-over-year from -$120.9 million in Q1 2025, and down 454.07% on a QoQ basis from $19.4 million in Q4 2025.
4D Molecular Therapeutics (FDMT) has 7 years of Consolidated Net Income data on file, last reported at -$68.8 million in Q1 2026.
- Quarterly Consolidated Net Income fell 43.13% year-over-year to -$68.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160.8 million (up 8.87% YoY) and the FY2025 annual result came in at -$140.1 million, up 12.89% from the prior year.
- Consolidated Net Income slipped to -$68.8 million in Q1 2026 per FDMT's latest filing, from $19.4 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $19.4 million in Q4 2025 and bottomed at -$68.8 million in Q1 2026.
- The 5-year median for Consolidated Net Income is -$32.3 million (2023), against an average of -$34.0 million.
- The widest annual swing landed in 2024, when Consolidated Net Income sank 334.17%; it then jumped 139.11% in 2025.
- Tracing FDMT's Consolidated Net Income over 5 years: stood at -$27.4 million in 2022, then dropped by 17.86% to -$32.3 million in 2023, then tumbled by 53.85% to -$49.6 million in 2024, then jumped by 139.11% to $19.4 million in 2025, then slumped by 454.07% to -$68.8 million in 2026.
- Per Business Quant, the three latest FDMT Consolidated Net Income figures stand at -$68.8 million (Q1 2026), $19.4 million (Q4 2025), and -$56.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | 4D Molecular Therapeutics | 674.52 Mn | 674.52 Mn | - | -68.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.76 Mn |
| Dec 31, 2025 | 19.42 Mn |
| Sep 30, 2025 | -56.86 Mn |
| Jun 30, 2025 | -54.60 Mn |
| Mar 31, 2025 | -48.04 Mn |
| Dec 31, 2024 | -49.65 Mn |
| Sep 30, 2024 | -43.84 Mn |
| Jun 30, 2024 | -34.91 Mn |
| Mar 31, 2024 | -32.39 Mn |
| Dec 31, 2023 | -32.27 Mn |
| Sep 30, 2023 | -10.10 Mn |
| Jun 30, 2023 | -29.62 Mn |
| Mar 31, 2023 | -28.66 Mn |
| Dec 31, 2022 | -27.38 Mn |
| Sep 30, 2022 | -25.70 Mn |
| Jun 30, 2022 | -28.09 Mn |
| Mar 31, 2022 | -26.29 Mn |
| Dec 31, 2021 | -25.08 Mn |
| Sep 30, 2021 | -22.23 Mn |
| Jun 30, 2021 | -7.59 Mn |
| Mar 31, 2021 | -16.31 Mn |
| Dec 31, 2020 | -20.42 Mn |
| Sep 30, 2020 | -7.81 Mn |
| Jun 30, 2020 | -15.14 Mn |
| Mar 31, 2020 | -13.15 Mn |